Perrigo (PRGO) Q2 2026 earnings review
Core Margins Compress Despite Divestiture Windfall
Perrigo posted a mixed Q2 that looks better on the surface than underneath. While reported EPS of $0.63 reversed a prior-year loss—heavily distorted by a gain from the Dermacosmetics divestiture—underlying profitability tells a different story. Core Adjusted Operating Margin experienced a Decelerating trend, dropping 160 bps to 13.0%, crushed by the carry-over impact of plant under-absorption and soft consumer consumption. The standout bright spot was a Reversing trend in Infant Formula, which surged 23% in sales and returned to operating profitability. Management reaffirmed FY26 guidance, betting heavily on a second-half volume recovery, but weak core OTC sales suggest this transition is far from over.
🐂 Bull Case
After quarters of dragging down earnings, Infant Formula flipped to positive operating income ($4M vs -$12M YoY) on the back of 23.1% sales growth, driven by contract timing and store brand momentum.
The successful closure of the Dermacosmetics divestiture provides ~$359M in cash proceeds, which is being deployed immediately to pay down debt, securing the company's path toward its 4.0x leverage target.
🐻 Bear Case
Lower production volumes from prior periods continue to haunt the P&L. This 'planned under-absorption' resulted in a $0.18 EPS hit in Q2 and continues to suffocate gross profit flow-through.
Despite management claiming share gains, both Self Care (-3.7%) and Specialty Care (-2.8%) posted negative revenue growth, highlighting severe macro softness in consumer health categories.
⚖️ Verdict: 🔴
Bearish. Management boasts of 'strengthening underlying fundamentals,' but the data shows Core organic sales shrinking 3.5% and Core adjusted operating margins dropping 160 bps. The reaffirmed annual guidance relies on a heroic second-half acceleration that current trends simply do not support.
Key Themes
Specialty Care Profitability Plunge
A major contradiction emerged in the Specialty Care segment. Management highlighted growth in Women's Health driven by the innovative Opill (the first OTC daily oral contraceptive) and ellaOne. However, segment operating income suffered a Decelerating trend, plunging 27.9% YoY to $48M on only a 2.8% sales decline. The margin collapse (from 28.4% down to 21.1%) was driven by unfavorable mix, plant under-absorption, and elevated advertising/promotional investments. This aggressive spending needs to yield immediate H2 results to justify the margin sacrifice.
Infant Formula Finally Reversing
After prolonged structural challenges and a strategic review announcement, the Infant Formula segment showed a Reversing trend. Net sales jumped 23.1% to $101M, driven by favorable timing of contract shipments and increased store brand formula sales. More importantly, operating income flipped from a $12M loss in the prior year to a $4M profit. Lapping isolated production variability (scrap costs) from the prior year significantly aided this comparison.
The Under-Absorption Anchor
The company remains trapped in a Stable negative trend of 'planned under-absorption'—a margin penalty caused by lower factory utilization in prior periods due to weak demand. This created an $0.18 negative EPS impact in Q2 (following $0.26 in Q1). Management expects this headwind to moderate in the second half, but it currently obscures any benefits from the ongoing Operational Enhancement Program.
Macro: Broad-Based Category Softness
Management explicitly cited 'ongoing category softness and macroeconomic headwinds' as the primary drag on top-line performance. The Self Care segment organic net sales fell 3.9%, driven by lower consumption in the U.S. and Europe, plus a delayed start to summer seasonal categories. Consumers remain pressured, leading to continued retail inventory destocking, especially in Europe.
Execution Risk on Reaffirmed Guidance
By reaffirming the FY26 Core Adjusted EPS guidance of $2.25-$2.55, management has set up a massive hurdle for the second half. With H1 Core EPS totaling just $0.86, Perrigo must generate roughly $1.39-$1.69 in H2. Given the Decelerating core revenue trends and persistent macro weakness, relying on this hockey-stick recovery is a major red flag for investors.
Portfolio Streamlining Yields Debt Reduction
The successful divestiture of the Dermacosmetics business generated a massive accounting gain and, more importantly, ~$359M in cash proceeds. A Stable trend in disciplined capital allocation continues, with the substantial majority of these proceeds applied directly to revolving credit facilities, structurally reducing net interest expense and keeping the company on a glide path toward its 4.0x net leverage target.
Other KPIs
Decreased 16.2% YoY. Gross profit flow-through collapsed due to a 3.9% organic sales drop, unfavorable product mix, and manufacturing under-absorption. Cost savings from the Operational Enhancement Program only partially offset these deep fundamental headwinds.
A solid quarter of cash generation brought six-month operating cash flow to $(31.0) million, marking a Reversing trend from the deep outflows of Q1. Management continues to target full-year cash from operating activities in the mid-60% range of adjusted net income.
Guidance
Stable (reaffirmed). With H1 generating only $0.86, this implies an Accelerating H2 requirement of roughly $1.39 to $1.69. Management expects this will be driven by moderating plant under-absorption costs and easier YoY category comparisons.
Stable (reaffirmed). Through H1, Core Organic growth is running below the midpoint of this range, meaning a return to flat or positive volume growth is required in H2 to meet targets.
Stable (reaffirmed). This indicates management expects a massive margin step-up in H2, as Q2 came in at just 13.0%. This heavily depends on the promised phase-out of under-absorption penalties.
Key Questions
Infant Formula Strategic Review Timeline
Given the sudden 23% revenue growth and return to operating profitability in the Infant Formula segment this quarter, how does this alter the timeline, valuation expectations, or ultimate desired outcome of the ongoing strategic review?
Specialty Care Margins vs Growth
Specialty Care operating margins fell severely due in part to A&P investments to support second-half growth. If category consumption remains soft, will you pull back on this A&P spend to protect the 15-16% Core margin target, or accept lower margins to defend market share?
H2 EPS Hockey-Stick
Achieving the midpoint of your reaffirmed EPS guidance requires generating nearly 65% of full-year profits in the second half. Aside from the mathematical roll-off of the under-absorption penalty, what tangible consumer demand signals give you confidence in this steep ramp?